1 / 23

Safety of smoking cessation medications

Safety of smoking cessation medications. Safety section. Chair Neal Benowitz University of California San Francisco, USA Carolyn Dresler Arkansas Department of Health, USA Steve S Hecht University of Minnesota, USA John Hughes University of Vermont, USA

joan-benjamin
Download Presentation

Safety of smoking cessation medications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Safety of smoking cessation medications

  2. Safety section Chair Neal Benowitz University of California San Francisco, USA Carolyn Dresler Arkansas Department of Health, USA Steve S Hecht University of Minnesota, USA John Hughes University of Vermont, USA Anne M Joseph Minneapolis VA Medical Center, USA Jacques Le Houezec Freelance consultant (France), and University of Nottingham, UK Cheryl Oncken University of Conneticut, USA Maxine Stitzer Johns Hopkins University, USA

  3. Nicotine vs. tobacco smoke • The main adverse effect of nicotine from tobacco is addiction, which sustains tobacco use1-2 • Other toxicants in tobacco smoke, not nicotine, are responsible for majority of adverse health effects3,4 • > 4000 different chemicals • tar, carbon monoxide, irritant and oxidant gases • > 80 carcinogens (11 are group 1 carcinogens)5 • Nicotine dependence leads to continued exposure to toxicants in tobacco smoke 1 USDHHS. The Health Consequences of Smoking: Nicotine Addition. 1988. 2 Royal College of Physicians. London: 2008. 3 Benowitrz. In Nicotine Safety and Toxicity; pp 185–195 NY: OUP. 4 Hoffman and Hoffman. J Toxicol Environ Health 1997; 50: 307–64. 5 Smith et al. Food Chem Toxicol 2003; 41: 807–817.

  4. Nicotine and cancer • Nicotine per se is not a substantial cause of cancer1-2 • Any cancer-related risks from short-term NRT are insignificant compared to the risks of smoking • Other tobacco smoke constituents are believed to be responsible for cancers3,4 1 US Department of Health and Human Services, Bethesda, MD, 2001. 2 Surgeon General's report 2010 3 Hoffman and Hecht. IN Handbook of Experimental Pharmacolgy, pp 63–102; 1990 Heidelberg: Springer-Verlag 4 Hecht. J Natl Cancer Inst. 1999; 91: 1194–1210.

  5. Nicotine and cancer • Studies carried out in rodents demonstrate that under normal conditions nicotine is not carcinogenic1 • Carcinogenic, nicotine-derived nitrosamines may be formed in the body under certain conditions2–4 • levels would be low and represent minimal risk during short term NRT • further research required to establish any risk associated with long term use of NRT • Nicotine can inhibit apoptosis (cell death) and enhance angiogenesis in cell and experimental animal test systems5-9 • This could in theory promote the spread of cancers. However this risk has not been documented in people 5 Porubin et al. J Agric Food Chem, 2007; 55: 7199-7204. 6 Stepanov et al. Cancer Res. 2009; 69: 8236-8240. 7 Cooke. Life Sci, 2007; 80: 2347-2351. 8 West et al. J Clin Invest, 2003; 111: 81-90. 9 Dasgupta et al. Proc Natl Acad Sci USA, 2006; 103: 6332-6337. 1 US Department of Health and Human Services, Bethesda, MD, 2001. 2 Benowitz et al. J Pharmacol Exp Ther 1994; 268: 296–303. 3 Hecht et al. Proc Natl Acad Sci USA. 2000; 97: 12493-12497. 4 Carmella et al. Carcinogenesis 1997; 18: 101–106.

  6. Smoking and cardiovascular disease • Smoking increases risk of CVD • Smoking-related factors contributing to CV risk: • increased thrombogenesis • carbon monoxide • oxidative damage • hyperlipidaemia • Smoking cessation significantly reduces risk within 1–3 years1-2 • Smoking cessation using NRT has a favourable effect on these contributing factors3 1 Rosenberg et al. N Engl J Med. 1990; 322: 213–217. 2 Rosenberg et al. N Engl J Med. 1985; 313: 1511–1514. 3 Ludviksdottir et al. J Intern Med. 1999; 246: 61–66.

  7. NRT and cardiovascular disease • NRT can be used safely by majority of people with cardiovascular disease, even with concomitant smoking1–3 • Meta-analyses show no difference in rate of acute MI between NRT patch and placebo4-6 • N.B. majority of studies excluded patients with CVD at baseline • The benefits of NRT outweigh the risks, even in smokers with cardiovascular disease7–9 5 Mills et al. Tob Induc Dis. 2010; 8: 8. 6 Hays & Ebbert. Drugs. 2010; 70: 2357-2372. 7 Benowitz. Prog Cardiovasc Dis. 2003; 46: 91-111. 8 Joseph & Fu. Prog Cardiovasc Dis. 2003; 45: 429-441. 9 Hubbard et al. Tob Control. 2005; 14: 416–21. 1 Joseph et al. N Engl J Med. 1996; 335:1792–1798. 2 Tzivoni et al. Cardiovasc Drugs Ther. 1998; 12:239–244. 3 Working Group. Arch Intern Med. 1994; 154:989–995. 4 Greenland et al. Drug Saf. 1998; 18: 297–308.

  8. Smoking, NRT and pregnancy • Maternal smoking is associated with poor pregnancy and childhood outcomes1–5 • Many toxicants in tobacco smoke could be responsible • Nicotine is a potential foetal teratogen • Nicotine may contribute to obstetrical complications in pregnant women and to sudden infant death syndrome6,7 • Benefits of NRT outweigh the risks of smoking during pregnancy8 • reduce or eliminate the exposure of fetus to other toxicants in tobacco smoke • reduce overall dose and duration of exposure to nicotine 5 Romano et al. Pediatrics, 2006; 117: 2101-2110. 6 Slotkin et al.. Brain Res Bull. 1995; 38: 69-75. 7 Slotkin et al. Neuropsychopharmacology. 2006; 31: 2462-2475. 8 Benowitz & Dempsey. Nicotine Tob Res. 2004; 6 Suppl 2: S189-202. 1 USDHHS. Surgeon General's Report. 2001. 2 Steyn et al. Paediatr Perinat Epidemiol. 2006; 20: 90-99. 3 Fried et al. Neurotoxicol Teratol. 1998; 20: 293-306. 4 Jacobsen et al. Neuropsychopharmacology. 2007; 32: 2453-2464.

  9. Nicotine replacement therapy • NRT delivers nicotine without the toxicants from tobacco1 • NRT helps combat the symptoms of withdrawal2 • Nicotine dose from NRT is lower and administered more gradually than with smoking and this reduces the addictive potential1,3 1 Benowitz & Gourlay. J Am Coll Cardiol. 1997; 29: 1422-1431. 2 Silagy et al. Cochrane Database Syst Rev. 2004; (3): CD000146. 3 Le Houezec. Int J Tuberc Lung Dis. 2003; 7: 811-819.

  10. Plasma nicotine levels (smoking and NRT) 14 12 10 8 Increase in nicotine concentration ( ng/ml ) Cigarette Gum 4 mg Gum 2 mg Inhaler Nasal spray Patch 6 4 2 0 5 10 15 20 25 30 Minutes Source: Balfour DJ & Fagerström KO. Pharmacol Ther. 1996; 72: 51-81.

  11. Abuse liability of NRT • Prevalence of abuse and dependence with current NRT products is nil (patch) or very low (<10% gum, nasal spray, inhaler)1 • Likely to be greatest with products that deliver nicotine rapidly, but less than that of cigarettes2–4 • Even if dependence develops, there is likely to be overall health benefit if individual no longer smokes 1 West et al. Psychopharmacology. 2000; 149: 198-202. 2 Stitzer & de Wit. In: Benowitz, NL. Nicotine Safety and Toxicity. pp. 1998 119-131 New York, Oxford University Press. 3 Henningfield & Keenan. J Consult Clin Psychol. 1993; 61: 743-750. 4 Hughes. In Nicotine Safety and Toxicity, 1998; pp. 147-157. New York: OUP

  12. Safety of Bupropion • Bupropion is generally well tolerated by smokers • The benefits of buproprion to aid smoking cessation outweigh the risks of buproprion in most smokers1–3 • Clinical trials of bupropion in smokers with cardiovascular disease found no significant adverse cardiovascular side effects4-5 • Data on safety in pregnancy are inconclusive • Bupropion appears not to have significant abuse liability6–9 6 Peck et al. Br J Clin Pharmacol. 1979; 7: 469-78. 7 Miller & Griffith. Psychopharmacology. 1983; 80: 199-205. 8 Margolin et al. Drug Alcohol Depend. 1995; 40: 125-31. 9 Rush et al. Exp and Clin Psychopharmacol. 1998; 6: 32-44. 1 Hurt et al. N Engl J Med. 1997; 337: 1195-1202. 2 Jorenby et al. N Engl J Med. 1999; 340: 685-691. 3 Cox et al. J Gen Intern Med. 2004; 19: 828-834. 4 Joseph & Fu. Prog Cardiovasc Dis. 2003; 45: 429-441. 5 Tonstad et al. Eur Heart J. 2003; 24: 946-955.

  13. Safety of Varenicline • Varenicline is generally well tolerated by smokers1-3 • The most common side effect is nausea (30-40%), sometimes with vomiting4-6 • Varenicline is licensed for all smokers 18, except those with severe renal impairment, pregnant or breastfeeding smokers • Warnings have been issued after a number of reports of psychiatric disturbances, including suicide in smokers taking varenicline, but not observed in studies7-8 5 Jorenby et al. JAMA. 2006; 296: 56-63. Erratum in: JAMA, 2006; 296: 1355. 6 Tonstad et al. JAMA. 2006; 296: 64-71. 7 Gunnell et al. BMJ. 2009; 339: b3805. 8 Stapleton et al. Addiction. 2008; 103: 146-154. 1 Williams et al. Curr Med Res Opin. 2007; 23: 793-801. 2 Cahill et al. Cochrane Database Syst Rev. 2011; (2): CD006103. 3 Stapleton et al. Addiction. 2008; 103: 146-54. 4 Gonzales et al. JAMA. 2006; 296: 47-55.

  14. Safety of other medications • Nortriptyline, moclobemide and clonidine have been found in smoking cessation trials in healthy smokers to be safe in doses approved for the treatment of depression/hypertension1-5 • Not approved by regulatory authorities for such use • All of these drugs are associated with severe toxicities in overdose 1 Hughes et al. Cochrane Database Syst Rev. 2007; (1): CD000031. 2 Hughes et al. Nicotine Tob Res. 2005; 7: 491-499. 3 Berlin et al. Clin Pharmacol Ther. 1995; 58: 444-452. 4 Gourlay et al. Cochrane Database Syst Rev. 2004; (3): CD000058. 5 Fiore. Respir Care. 2000; 45: 1200-1262.

  15. Concomitant smoking • Concomitant use of NRT, bupropion or varenicline and smoking is well tolerated1–7 • Number of cigarettes smoked is likely to be less than at baseline • This might result in reduced health hazards • Such benefit has yet to be scientifically demonstrated • NRT-assisted reduction does increase later quitting8-12 7 Jorenby et al. JAMA. 2006; 296: 56-63. 8 Bolliger et al. BMJ. 2000; 321: 329-333. 9 Wennike et al. Addiction. 2003; 98: 1395-1402. 10 Batra et al. Clin Pharmacol Ther. 2005; 78: 689-696. 11 Rennard et al. Nicotine Tob Res. 2006; 8: 555-564. 12 Kralikova et al. BMC Public Health. 2009; 9: 433. 1 Benowitz et al. J Pharmacol Exp Ther. 1998; 287: 958-962 2 Bjornson-Benson et al. Addict Behav. 1993; 18: 491-502. 3 Hurt et al. N Engl J Med. 1997; 337: 1195-202. 4 Jorenby et al. N Engl J Med. 1999; 340: 685-91. 5 Zevin et al. Clin Pharmacol Ther. 1998; 64: 87-96. 6 Gonzales et al. JAMA. 2006; 296: 47-55.

  16. ‘Reduced risk’ cigarettes • Includes low tar and ‘light’ cigarettes, and novel products that deliver nicotine with minimal tobacco combustion • Low tar cigarettes have not be shown to substantially reduce health hazards of smoking but do provide sufficient nicotine to sustain addiction1-6 • Some novel products may deliver fewer or lower levels of toxicants but some deliver more carbon monoxide. Not shown to reduce risk of smoking or aid cessation7-9 • Smoking cessation medications are most likely safer than any ‘reduced risk’ cigarette 1 NCI Monograph 13. 2001. 5 Bernert et al. Nicotine Tob Res. 2005; 7: 729-738. 2 NCI Monograph 7. 1996. 6 Blackford et al. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1799-1804. 3 Hecht et al. Cancer Epidemiol Biomarkers Prev. 2005; 14: 693-698. 7 Fagerström et al. Tob Control. 2000; 9: 327-333. Erratum in: Cancer Epidemiol Biomarkers Prev. 2006; 15: 1568. 8 Pauly et al. Cancer Epidemiol Biomarkers Prev. 1998; 7: 967-979. 4 Benowitz et al. Cancer Epidemiol Biomarkers Prev. 2005; 9 Buchhalter & Eissenberg. Nicotine Tob Res. 2000; 2: 39-43. 14: 1376-1383.

  17. Electronic Nicotine Delivery Devices • Electronic Nicotine Delivery Devices are basically oropharyngeal nicotine delivery devices • Systemic dose of nicotine obtained with ENDD is relatively small, but amount of nicotine in the cartridge is substantial (up to 16-18 mg)1 • Small amounts of contaminants (e.g. TSNA) found in some products which raise health concerns2 • some case reports, surveys and small studies seem to indicate that it may help smokers to quit smoking3-6 • Standardisation of products (regulatory oversight) and clinical and non-clinical studies are needed2 1 Bullen et al. Tob Control. 2010; 19: 98-103. 4 Siegel et al. Am J Prev Med. 2011; 40: 472-475. 2 Etter et al. Tob Control. 2011; 20: 243-248. 5 Trtchounian et al. Nicotine Tob Res. 2010; 12: 905-912. 3 Etter. BMC Public Health. 2010; 10: 231. 6 Vansickel et al. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1945-1953.

  18. Smokeless tobacco • Snuff or chewing tobacco has been suggested as a potential aid to harm reduction or smoking cessation1 • However, such products known to cause oral cancer2–3 • Country variation in composition may mean toxicity of smokeless tobacco products varies4–7 • Smokeless tobacco is addictive and not recommended for smoking cessation • Safety and efficacy of NRT, bupropion, and varenicline are better demonstrated 1 Radical strategies for prevention and harm reduction in nicotine addiction. Royal College of Physicians; 2008. 2 International Agency for Research on Cancer. IARC Monographs Vol. 89. Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines. 2007. 3 US Surgeon General. Public Health Service, Bethesda, MD, NIH Publ. No. 86-2874, 1986 4 Hecht. Chem Res Toxicol. 1998; 11: 559-603. 5 Hoffmann et al. J Natl Cancer Inst. 1995; 87: 1832-1869. 6 Osterdahl. International Agency for Research on Cancer Scientific Publications 105, 235-237, 1991. 7 Stepanov et al. Nicotine Tob Res. 2008; 10: 1773-1782.

  19. Long-term pharmacotherapy • Goal of long-term pharmacotherapy is to replace smoking1-3 • Long-term use of NRT, bupropion or varenicline is likely to be much safer than smoking but efficacy has not yet been demonstrated4-7 • Experience with long term buproprion use for depression suggests it is well tolerated6 • Evidence of a persistent health risk, even with prolonged reduction of cigarette consumption8 1 Anderson & Hughes. Addiction. 2000; 95 Suppl 1: S9-11. 2 IOM report. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington DC, 2001. 3 Radical strategies for prevention and harm reduction in nicotine addiction. Royal College of Physicians; 2008. 4 Stead & Lancaster. Cochrane Database Syst Rev. 2007; (3): CD005231. 5 Murray et al. Chest. 1996; 109: 438-445. 6 Cox et al. J Gen Intern Med. 2004; 19: 828-834. 7 Tonstad et al. JAMA. 2006; 296: 64-71. 8 Godtfredsen et al. J Epidemiol Community Health. 2003; 57: 412-416.

  20. Safety in adolescents • Many adolescents are addicted to nicotine1 • Little reason to believe that any risk associated with NRT, bupropion or varenicline is greater in adolescents who smoke than in adults who smoke • Efficacy of NRT and bupropion in adolescents is unclear2-10 • Efficacy of varenicline in adolescents has not been studied 6 Monuteaux et al. J Clin Psychiatry. 2007; 68: 1094-1101. 7 Moolchan et al. Pediatrics. 2005; 115: e407-e414. 8 Muramoto et al. Arch Pediatr Adolesc Med. 2007; 161: 1068-1074. 9 Roddy et al. Tob Control. 2006; 15: 373-376. 10 Upadhyaya et al. J Am Acad Child Adolesc Psychiatry. 2004; 43: 199-205. 1 USDHHS. A Report of the Surgeon General. 1994. 2 Colby & Gwaltney. JAMA. 2007; 298: 2182-2184. 3 Hanson et al. Nicotine Tob Res. 2003; 5: 515-526. 4 Hanson et al. Drug Alcohol Depend. 2008; 95: 164-168. 5 Killen et al. J Consult Clin Psychol. 2004; 72: 729-735.

  21. Recommendations • All smokers, even those with cardiovascular disease, should be offered nicotine replacement therapy, bupropion or varenicline to aid cessation. • Pregnant smokers should be encouraged to attempt cessation using educational and behavioral interventions before using pharmacological approaches. If such quit attempts are unsuccessful, the risks and benefits of pharmacotherapy should be considered and explained to the woman. The decision to use pharmacotherapy should be made on an individualized basis after discussion between the woman and her physician.

  22. Areas for further research • Safety of nicotine and other medications to aid smoking cessation in pregnant smokers, including impact on the health and development of newborns of mothers who received medication during pregnancy. • Preclincal and clinical studies on the role of nicotine vs other toxicants in the onset of SIDS. • Safety of bupropion in high risk groups (pregnancy, alcohol abuse, history of stroke or other brain injury). • Safety of varenicline in high risk groups (psychiatric disease, cardiovascular disease, alcohol and drug abuse, pregnancy) • Safety of nicotine and other medications to aid smoking cessation in adolescents. • Beneficial and harmful health effects of novel nicotine delivery devices, including their potential for use to initiate smoking (in adolescents), to increase overall nicotine intake via concurrent use with cigarettes, and potential adverse effects on smoking cessation (i.e. switching instead of quitting).

  23. Areas for further research • Development of biomarkers of exposure and surrogate markers of health effects of tobacco and related products. • Safety of long term nicotine replacement or other medication as would be used to reduce cigarette smoking or maintain tobacco abstinence. • Safety and efficacy of oral tobacco products (e.g. snus) for smoking cessation, for harm reduction or for withdrawal relief during temporary abstinence. • Does use of novel tobacco products or oral tobacco products for non-cessation reasons undermine motivation to quit? • More rigorous studies of the association of varenicline with psychiatric disorders, including prospective studies. • Better epidemiological studies of the association of smoking reduction and reduced risk of smoking.

More Related